The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 11, Issue 2, Pages 221-233
Publisher
Informa Healthcare
Online
2011-11-11
DOI
10.1517/14740338.2012.632631
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
- (2011) Catharine C. Bulik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
- (2011) Alison G. Freifeld et al. CLINICAL INFECTIOUS DISEASES
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
- (2011) Catherine Liu et al. CLINICAL INFECTIOUS DISEASES
- Influence of Empiric Therapy with a -Lactam Alone or Combined with an Aminoglycoside on Prognosis of Bacteremia Due to Gram-Negative Microorganisms
- (2010) J. A. Martinez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis
- (2010) M. Lefebvre et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Length of Stay and Hospital Costs Associated with a Pharmacodynamic-Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator-Associated Pneumonia
- (2010) Anthony M Nicasio et al. PHARMACOTHERAPY
- -Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli
- (2009) M. N. Al-Hasan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro 24-Hour Time-Kill Studies of Vancomycin and Linezolid in Combination versus Methicillin-Resistant Staphylococcus aureus
- (2009) S. R. Singh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Differing Effects of Combination Chemotherapy with Meropenem and Tobramycin on Cell Kill and Suppression of Resistance of Wild-Type Pseudomonas aeruginosa PAO1 and Its Isogenic MexAB Efflux Pump-Overexpressed Mutant
- (2009) G. L. Drusano et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin
- (2009) A.-K. John et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Initial Low‐Dose Gentamicin forStaphylococcus aureusBacteremia and Endocarditis Is Nephrotoxic
- (2009) Sara E. Cosgrove et al. CLINICAL INFECTIOUS DISEASES
- Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials
- (2009) Mary-Anne W. Aarts et al. CRITICAL CARE MEDICINE
- Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia*
- (2009) Young Ju Jung et al. CRITICAL CARE MEDICINE
- Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia
- (2009) Yasmin Maor et al. JOURNAL OF INFECTIOUS DISEASES
- Impact of Superinfection on Hospital Length of Stay and Costs in Patients with Ventilator-Associated Pneumonia
- (2009) Kathryn Eagye et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus
- (2008) D. J. Riedel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections
- (2008) Joshua Perlroth et al. ARCHIVES OF INTERNAL MEDICINE
- Increased Antimicrobial Susceptibility Profiles among Polymyxin‐ResistantAcinetobacter baumanniiClinical Isolates
- (2008) Rodrigo E. Mendes et al. CLINICAL INFECTIOUS DISEASES
- Severity of Gentamicin's Nephrotoxic Effect on Patients with Infective Endocarditis: A Prospective Observational Cohort Study of 373 Patients
- (2008) Kristine Buchholtz et al. CLINICAL INFECTIOUS DISEASES
- Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
- (2008) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Effect of antibiotics, alone and in combination, on Panton–Valentine leukocidin production by a Staphylococcus aureus reference strain
- (2008) O. Dumitrescu et al. CLINICAL MICROBIOLOGY AND INFECTION
- Acinetobacter baumannii: Emergence of a Successful Pathogen
- (2008) A. Y. Peleg et al. CLINICAL MICROBIOLOGY REVIEWS
- Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model
- (2008) Joon Young Song et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
- (2008) S. J. Rehm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus
- (2008) W. E. Rose et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Presence of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its Correlation with In Vitro Carbapenem Susceptibility
- (2008) J. Marschall et al. JOURNAL OF CLINICAL MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started